

Non-Interventional Post-Authorisation Safety Study (PASS) survey to evaluate the effectiveness of the Isatuximab Educational Materials, to minimise the Risk of Interference for blood typing (minor antigen) (positive indirect Coombs' test).

First published: 03/05/2022

Last updated: 23/04/2024

Study

Finalised

Administrative details

PURI

<https://redirect.ema.europa.eu/resource/48387>

EU PAS number

EUPAS46988

Study ID

48387

DARWIN EU® study

No

Study countries

Austria

France

Germany

Italy

Netherlands

Poland

Sweden

Switzerland
United Kingdom

Study description


The study aims to assess the effectiveness of the isatuximab Educational Materials in terms of process indicator, meaning implementation, knowledge and behaviour with respect to the safety messages conveyed in these materials.

Study status

Finalised

Research institution and networks

Institutions



Evidera
United Kingdom
First published: 20/11/2013
Last updated 07/03/2024

Institution

Laboratory/Research/Testing facility

Non-Pharmaceutical company

ENCePP partner

Contact details

Study institution contact

Delphine Saragoussi

Study contact

delphine.saragoussi@evidera.com

Primary lead investigator

Delphine Saragoussi

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:
24/09/2020

Study start date

Planned:
02/05/2022
Actual:
09/05/2022

Data analysis start date

Planned:
31/03/2023
Actual:
20/04/2023

Date of final study report

Planned:
01/02/2024
Actual:
22/08/2023

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Sanofi-Aventis Groupe

Study protocol

[Sanofi Isatuximab PASS survey protocol_PRAC_V1.4_21Oct2021_clean_EUPAS46988 for publication.pdf\(1.85 MB\)](#)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Main study objective:

The study aims to assess the effectiveness of the isatuximab Educational Materials in terms of process indicator, meaning implementation, knowledge and behaviour with respect to the safety messages conveyed in these materials.

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

ISATUXIMAB

Medical condition to be studied

Plasma cell myeloma

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

384

Study design details

Outcomes

The primary outcome will be the % of participants who correctly respond to the key knowledge question in the assessment of education materials survey. The secondary outcomes are in addition to the primary outcome, % of prescriber HCPs who also correctly respond to at least 5 of 7 behaviour questions in the assessment of education materials survey, or % of non-prescriber HCPs who also correctly respond to at least 2 of 3 behaviour questions in the assessment of education materials survey.

Data analysis plan

A description of the following outcomes of interest related to process indicators will be performed:

- Measures of the extent of implementation of the original plan, and/or variations in its delivery, at each participating country level.
- Knowledge and Behaviour.

Data management

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

LiveTracker™ panel

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No